01:40 PM EDT, 07/18/2025 (MT Newswires) -- The US Food and Drug Administration will ask Sarepta Therapeutics ( SRPT ) to voluntarily halt all shipments of Elevidys, its gene therapy for the treatment of Duchenne muscular dystrophy, Reuters reported Friday, citing a source familiar with the matter.

Sarepta didn't immediately reply to a request for comment from MT Newswires.

Shares were down over 38% in recent trading.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 13.51, Change: -8.46, Percent Change: -38.50